enGene Holdings Inc. (ENGN)
- Previous Close
8.40 - Open
8.43 - Bid 8.21 x 100
- Ask 8.38 x 100
- Day's Range
8.14 - 8.43 - 52 Week Range
4.42 - 47.17 - Volume
17,509 - Avg. Volume
177,543 - Market Cap (intraday)
370.916M - Beta (5Y Monthly) -0.68
- PE Ratio (TTM)
-- - EPS (TTM)
-2.79 - Earnings Date Sep 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
30.71
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
www.engene.comRecent News: ENGN
View MorePerformance Overview: ENGN
Trailing total returns as of 10/16/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ENGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ENGN
View MoreValuation Measures
Market Cap
371.41M
Enterprise Value
138.59M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.61
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-22.07%
Return on Equity (ttm)
-123.06%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-123.44M
Diluted EPS (ttm)
-2.79
Balance Sheet and Cash Flow
Total Cash (mrq)
257.68M
Total Debt/Equity (mrq)
10.79%
Levered Free Cash Flow (ttm)
-23.58M